Background: Prediction of metastatic outcome in sarcomas is challenging for clinical management since they are aggressive and carry a high metastatic risk. A 67-gene expression signature, the Complexity INdex in SARComas (CINSARC), has been identified as a better prognostic factor than the reference pathological grade. Since it cannot be applied easily in standard laboratory practice, we assessed its prognostic value using nanoString on formalin-fixed, paraffin-embedded (FFPE) blocks to evaluate its potential in clinical routine practice and guided therapeutic management.
Introduction
Adult soft-tissue sarcomas (STSs) are rare tumors (<1%) that form a heterogeneous group with more than 100 different pathological subtypes and an aggressive clinical course (40/ 50% metastases within 5 years of diagnosis) [1] . Clinical management consists in surgical resection with optional adjuvant therapies that depend on clinical characteristics, tumor histological type and histological grade [2] . The histological grading system of the FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) comprises three grades: low, intermediate and high risk of metastasis. It is at present the best predictor of metastatic relapse in early-stage sarcoma and the most influential for deciding on adjuvant chemotherapy [3] . However, it has several limitations. It is not applicable in all pathological subtypes, its reproducibility may vary between pathologists, it is poorly informative grade 2, which represents $40% of cases, and it is difficult to apply on tumor microbiopsies and on surgical specimens post neo-adjuvant therapy [4] . In 2010, our group identified and validated a 67-gene expression signature named CINSARC (Complexity Index in SARComas) that is a valuable prognostic factor in several sarcoma histotypes and outperforms histological grade [5] [6] [7] . CINSARC, in which genes are involved in mitotic control and chromosomal integrity, stratifies tumor prognosis into two groups ("low-risk, C1" and "high-risk, C2"), instead of three with the FNCLCC system, thus facilitating clinical management. It was first used on frozen tumors analyzed by microarrays and was subsequently applied on formalin-fixed, paraffin-embedded (FFPE) RNA-sequencing [8] . However, the RNA is degraded in more than half of all tested FFPE tumors so its routine use for clinical and therapeutic purposes has been limited until now. Indeed, the availability of freshfrozen tumor material is very low in daily routine practice. Archived FFPE tumor-tissue samples are available in anatomical pathology laboratories and tissue banks. Unfortunately, formalin fixation induces chemical modifications such as crosslinking between nucleic acids and proteins and RNA degradation, so the subsequent use of frozen tissue for genomic and transcriptomic applications such as microarrays and RNA sequencing is limited [9] . NanoString, a recently developed probe-based technique using direct digital measurement of transcript abundance with multiplexed color-coded probe pairs, has been shown to quantify mRNA expression accurately in FFPE and fragmented material [10, 11] . This feature of nanoString offers advantages compared with PCR-based methods, including the absence of amplification bias, which may be higher when using fragmented RNA isolated from FFPE blocks. Several publications have demonstrated the accuracy and precision of nanoString with FFPE material [10, 12, 13] . A code set comprising 67 probes derived from the 67 genes of the CINSARC signature was built and named NanoCind V R . Thus, the aim of the present study was to evaluate the prognostic value of the CINSARC signature established by nanoString (NanoCind V R ) on FFPE tumor blocks in order to use it in routine clinical practice to determine the risk of developing metastases and to guide personalized therapeutic management.
To compare the performance of RNA-seq and nanoString in establishing CINSARC-based risk, we applied both techniques on sarcoma cohorts with clinical annotations from the Conticabase (European sarcoma database). We tested a large cohort of 124 frozen samples and a subgroup of 45 samples together with matching FFPE blocks plus 20 additional FFPE core needle biopsies to test the performance of NanoCind V R on degraded material typical of that used in daily practice.
Materials and methods
More details are available in the Supplementary Methods file, available at Annals of Oncology online.
Cohorts and design
To evaluate the potential transfer of the CINSARC signature from RNAseq on fresh-frozen samples (FFSs) to nanoString on FFPE blocks, we used two independent cohorts. The first one which comprised 95 sarcomas was used in 2016 by Chibon's team to validate the transfer of CINSARC from microarrays to RNA-seq on FFS [8] . Of the 95 sarcomas described in that publication, FFS or RNA were still available for 77 cases. A second set of 47 sarcomas was added since RNA-seq expression on FFS (n ¼ 47) and FFPE (n ¼ 45) had already been tested by our team. Therefore, for the transfer from RNA-seq to nanoString, we analyzed a set of 124 (77 and 47) sarcomas (named cohort #1) by both RNA-seq and nanoString (NanoCind V R ) on FFS. To evaluate whether CINSARC had a prognostic value on FFPE tissue, we analyzed the 47 sarcomas plus 20 microbiopsies (cohort #2) with NanoCind V R on FFPE blocks. 
Tumor samples

NanoString CodeSet design and expression quantification
Our nCounter code set (NanoCind V R ) consisted of a panel of 75 probes, including 67 distinct test probes derived from 67 distinct genes (Supplementary Table S1 , available at Annals of Oncology online) and 8 housekeeping genes for biological normalization purposes.
Results
Cohorts
Tumor characteristics and follow-up of patients in both cohorts are presented in Table 1 .
NanoString nCounter gene expression system performance
First the reproducibility of the nCounter system in measuring the NanoCind V R panel was examined. The raw counts for all 75 genes on the same sample from two independent hybridizations of RNA from FFS are shown in Supplementary Figure S1A , available at Annals of Oncology online (between two independent cartridges) and S1B (in the same cartridge). A linear fit to the data resulted in a median Pearson's correlation coefficient of 0.9849 (inter-and intra-cartridges). Then, we examined the linearity and dynamic range of two FFS. Supplementary Figure S1 Technological transfer: from RNA-seq to nanoString (NanoCind V R )
We carried out comparisons of the same FFS (cohort #1, n ¼ 124) between both techniques. Pearson's correlation of 67 CINSARC gene expression values for the same high quality RNA samples between RNA-seq and nanoString was 0.797 6 0.130 (Supplementary Figure 2B , available at Annals of Oncology online). Thus, we aimed to test the prognostic value of CINSARC. An agreement test between the prognostic groups (CINSARC C1, low-risk and CINSARC C2, high-risk) by nanoString on FFS resulted in a similar CINSARC classification for 107 of 124 transcriptomic profiles (86% agreement; Cohen's kappa ¼ 0.687; P < 10
À10
) compared with RNA-seq classification on FFS. By combining associated clinical data outcome, we carried out metastasis-free survival analysis. NanoString had a significant prognostic value (P ¼ 1.01 Â 10
À2
, HR ¼ 2.9, 95% CI: 1.23-6.82) ( Figure 1A ) while RNA-seq did not (P ¼ 9.68 Â 10 
Material transfer: from fresh-frozen tissue to FFPE blocks
To optimize the quantity and quality of RNA extraction, we carried out different extractions on the same FFPE blocks with different commercial kits. Mean Pearson's correlation of the raw counts with the NanoCind V R panel for the High Pure FFPET RNA Isolation Kit, Roche (reference kit) compared with the Roche FFPET RNA Isolation Kit (used in Prosigna) (n ¼ 2) was 0.993 (Supplementary Figure S3A and B, available at Annals of Oncology online). Mean Pearson's correlation of the raw counts with the NanoCind V R panel for the High Pure FFPET RNA Isolation Kit, Roche (reference kit) compared with the RNeasy FFPE kit, Qiagen Kit (n ¼ 27) was 0.786 (range, 0.104-0.984) (Supplementary Figure S3C , available at Annals of Oncology online). Moreover, we assessed the stability of RNA from unstained slides following extraction at different times after cutting with a view to using this technique in routine practice. On the same FFPE block, we carried out RNA extractions on unstained slides the same day of the cut (J0, reference protocol) and 21 days room Finally, we carried out metastasis-free survival analysis of the pooled FFS and FFPE samples (n ¼ 141) with both RNA-seq and nanoString analyses ( Figure 1D ). Both techniques provided a significant prognostic value but the CINSARC signature with nanoString (NanoCind V R )(P ¼ 2.45 Â 10
À3
, HR ¼ 3.19, 95% CI: 1.43-7.08) was Figure S5B , available at Annals of Oncology online). Among the pooled FFS and FFPE samples (n ¼ 141) with data obtained by RNA-seq and nanoString, the FNCLCC histological grade was available for 116 cases. The CINSARC signature with nanoString (NanoCind V R ) discriminated two groups of low-and high-risk subjects with clearly significant and different outcomes (P ¼ 9.39 Â 10
, HR ¼ 3.58, 95% CI: 1.28-10, Figure 2A ), whereas its prognostic value with RNA-seq was not significant (P ¼ 1.16 Â 10
À1
, HR ¼ 1.74, 95% CI: 0.86-3.53, Figure  2B ) and histological grade (G1/G2 versus G3) did not predict outcome (P ¼ 6.58 Â 10
, HR ¼ 1.16, 95% CI: 0.6-2.26, Figure 2C ). Consequently, we also investigated the performance of CINSARC in subjects of the same histological grade and in grade 2 tumors, the CINSARC signature (NanoCind V R ) identified two groups of different outcomes with a significant prognostic value (P ¼ 5.16 Â 10
À4
, HR ¼ 15.73, 95% CI: 2.01-123.37, Figure 2D ).
Discussion
STSs are a group of rare, heterogeneous, aggressive tumors with high metastatic risk. The CINSARC signature outperforms histological grade for metastatic prognosis in several cancer types and especially in STS [5] [6] [7] . Nevertheless, it is not applicable in routine clinical practice because it was developed and validated in microarrays and RNA-sequencing, which are techniques requiring large amounts of high-quality RNA, especially from freshfrozen tumor tissue. In the current study, the CINSARC signature established by nanoString (NanoCind V R ) on FFPE blocks was a strong predictor for metastatic events (which outperformed histological grade) and is therefore usable in routine clinical settings.
In the first part of the CINSARC transfer, CINSARC gene expression values correlated well using these two techniques (mean Pearson's r is 0.797 between RNA-seq and nanoString), which is consistent with already published methodological correlations [10] [11] [12] [13] . Furthermore, similar risk-group classifications (86%) were noted. However, while its prognostic value with RNA-seq was nonsignificant (reference technique, P ¼ 9.68 Â 10 À2 ), it was significant with nanoString (eP ¼ 1.01 Â 10
À2
). In recent decades, high-throughput molecular analyses, especially gene expression profiling, have led to the identification of specific gene expression signatures as a prognostic factor in several malignancies such as breast cancer and lymphoma [14, 15] . For example, several multigene signatures such as Oncotype TM or Prosigna TM are marketed for early-stage breast cancer and are used in routine practice for therapeutic management [16] . No similar signature is currently available in routine practice for sarcoma patients. Indeed, although Chibon et al. [5] identified and validated a prognostic molecular signature in sarcomas (CINSARC) in 2010, they worked on frozen tumor material that was evaluated by microarrays, a technique that is not widely available. Moreover, several studies have shown the validity of the CINSARC signature [5-7, 17, 18] , in accordance with the REMARK criteria for replicability of biomarker signatures [19] . In 2016, Lesluyes et al. successfully transferred the signature using RNA-seq with frozen tissues. However, their attempt to adapt it on FFPE blocks was disappointing with more than 50% of FFPE cases that could not be analyzed with RNA-seq owing to degradation of RNA induced by formalin [8] . In our study, all (n ¼ 67) FFPE blocks (the same cases as those tested by Lesluyes et al., except microbiopsies) were analyzable with nanoString. Moreover, in terms of prognosis, the CINSARC signature obtained with nanoString (NanoCind V R ) from RNA extracted from FFPE blocks had a significant prognostic value (P ¼ 1.13 Â 10 À2 , HR ¼ 4.43, 95% CI: 1.125-15.72), allowing its use in routine practice. The low quality of RNA extracted from FFPE blocks did not influence the efficiency of the results when nanoString was used. These findings are in accordance with previous studies reporting the robust performance of nanoString on RNA extracted from FFPE material with results comparable to those obtained with RNA from fresh-frozen tissue by microarrays [13] . Indeed, nanoString Figure 2 . Metastasis-free survival analysis (fresh-frozen samples, cohort #1 and FFPE samples, cohort #2) according to CINSARC signature using nanoString expression data (NanoCind V R ) (A), RNA-seq expression data (B) and FNCLCC grade (C). (D) Metastasis-free survival analysis according to CINSARC signature using nanoString expression data (NanoCind V R ) on grade 2 FNCLCC cases.
does not require reverse transcription of mRNA and subsequent cDNA amplification. This feature offers advantages over NGS and PCR-based methods, including the absence of amplification bias, which may be higher when using fragmented RNA isolated from FFPE specimens. This could explain the few discordant classifications we observed and particularly why poor prognosis patients were classified as "good" prognosis by the RNA-seq approach. The value and the superiority of nanoString (NanoCind V R ) were confirmed by three of our results: first, it gave a significant prognostic value which was more discriminating than that established by RNA-seq (P ¼ 2.45 Â 10 À3 versus P ¼ 3.42 Â 10 À2 ); second, it outperformed the current histological grade (FNCLCC) (P ¼ 9.39 Â 10 À3 versus P ¼ 6.58 Â 10
À1
) and third, in grade 2 (FNCLCC) tumors, it clearly and significantly differentiated two groups of different outcomes (P ¼ 5.16 Â 10 À4 ). Its advantage over histologic grading is that it stratifies patients into two groups instead of three, which is essential for facilitating clinical management. A major point that we have started to test is its applicability to microbiopsies, which is at present the gold standard in terms of STS management [1] . All 20 cases (FFPE, microbiopsies) could be analyzed using nanoString, despite somewhat degraded samples with limited amounts of RNA. Moreover, among the 20 FFPE microbiopsies, three patients have metastases and these three tumors were classified as "poor outcome" by nanoString.
To be able to use this signature in routine clinical practice, we tested it in several conditions. It showed excellent reproducibility (replicates averaging R 2 of 0.983) and robustness, consistent with previous reports [10] . Moreover, we tested three different commercial nucleic acid extraction kits for FFPE material. The two we tested demonstrated good results with high (Pearson's r ¼ 0.786 for RNeasy FFPE kit, Qiagen) to excellent (Pearson's r ¼ 0.993 for Roche FFPET RNA Isolation Kit, used in Prosigna) correlation. Finally, the test turnaround time with nanoString is shorter than for NGS approaches; library preparation and nucleic acid amplification are not required and the complexity of data analysis is negligible compared with NGS, which requires a specialized bioinformatics pipeline and sequence analysis strategies.
Conclusion
In conclusion, the CINSARC signature, which can now be determined using FFPE samples with nanoString (NanoCind V R ), has reached another step towards its use in routine practice. Following on from recent data demonstrating that it is an excellent prognostic marker of clinical outcome in many other human malignancies [17] , it can now be tested and validated on other independent cancer-specific cohorts with FFPE blocks. In patients with STS, its prognostic value has been widely confirmed and it seems to be better than FNCLCC grade, as suggested by the present study and previously observed [5, 7] . Above all, the CINSARC signature could overcome one of the major limitations of FNCLCC grading by splitting patients with FNCLCC grade 2 STS into two separate prognostic groups that could then benefit from different therapeutic strategies. Furthermore, a French Sarcoma Group study aiming to tailor treatment based on the CINSARC signature will soon begin. Finally, as expected since several publications have demonstrated the accuracy and precision of nanoString in small samples with limited amounts of RNA such as tissue biopsies [10, 12, 13] , our preliminary data on 20 cases suggest that Nanocind V R is feasible in FFPE microbiopsies, i.e. the standard approach in STS diagnosis [1] . Further NanoCind V R evaluation in a larger cohort of FFPE microbiopsies is currently ongoing and will be the final step to consider full CINSARC routine evaluation and global use.
